Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 5/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | DHFR | P00374 | 9/20 | 0.47 |
| ▸ | GART | P22102 | 5/20 | 0.47 |
| ▸ | ATIC | P31939 | 4/20 | 0.47 |
| ▸ | TLR4 | O00206 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5665622 | 1.00 | TYMS (0.66) | TYMSKDM4EMEN1ALDH1A1POLB | |
| Folic Acid SCHEMBL8897352 | 0.93 | TYMS (0.80) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL16681740 | 0.89 | AKR1B1 (0.51) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL609951 | 0.85 | AKR1B1 (0.49) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL16058737 | 0.85 | AKR1B1 (0.49) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL17811602 | 0.83 | AKR1B1 (0.45) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL2906514 | 0.83 | TYMS (0.62) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL27812907 | 0.82 | TYMS (0.62) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL7639622 | 0.81 | AKR1B1 (0.46) | TYMSKDM4EMEN1ALDH1A1POLB | |
| Dihydrofolic Acid SCHEMBL7522026 | 0.81 | TYMS (0.66) | TYMSKDM4EMEN1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122532-A1 | VIRAL VECTORS AND PACKAGING CELL LINES | UMOJA BIOPHARMA, INC. | 2025-04-17 | — | — | US | disclosed |
| US-20250122533-A1 | VIRAL VECTORS AND PACKAGING CELL LINES | UMOJA BIOPHARMA, INC. | 2025-04-17 | — | — | US | disclosed |
| US-12215337-B2 | Viral vectors and packaging cell lines | UMOJA BIOPHARMA, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| CN-118459590-A | Anti-BTN 3A antibodies and their use in the treatment of cancer or infectious disorders | 感应检查疗法公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-113286819-B | Anti-BTN 3A antibodies and their use in the treatment of cancer or infectious disorders | 感应检查疗法公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20240122978-A1 | RETROVIRAL VECTOR FOR UNIVERAL RECEPTOR THERAPY | UMOJA BIOPHARMA, INC. | 2024-04-18 | — | — | US | disclosed |
| US-20230407330-A1 | VECTOR SYSTEM FOR DELIVERY OF MULTIPLE POLYNUCLEOTIDES AND USES THEREOF | UMOJA BIOPHARMA, INC. (US) | 2023-12-21 | — | — | US | disclosed |
| EP-4247963-A1 | VECTOR SYSTEM FOR DELIVERY OF MULTIPLE POLYNUCLEOTIDES AND USES THEREOF | Umoja Biopharma, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-4045663-A2 | RETROVIRAL VECTOR FOR UNIVERAL RECEPTOR THERAPY | Umoja Biopharma, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2022109162-A1 | VECTOR SYSTEM FOR DELIVERY OF MULTIPLE POLYNUCLEOTIDES AND USES THEREOF | UMOJA BIOPHARMA, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240122978-A1 | RETROVIRAL VECTOR FOR UNIVERAL RECEPTOR THERAPY | CD4, HAVCR2, CD40 | TYMS 589/4885KDM4E 3293/4885MEN1 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.